ArticleBMC pregnancy and childbirth2025
Predictive value of maternal serum placental growth factor, maternal clinical features, and fetal ultrasound indicators in preeclampsia.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Untargeted metabolomics for the early detection of preeclampsia: A systematic review of human studies.PloS one · 2026Pooled it
- Trajectories of Maternal Placental Growth Factor Levels from Early to Late Pregnancy: Prenatal Factors and Adverse Perinatal Outcomes.International journal of women's health · 2026Article
- Serum uric acid as a diagnostic biomarker for preeclampsia: comparison with renal indices and cerebroplacental ratio.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study was aimed to evaluate the predictive value of placental growth factor (PLGF), maternal risk factors, and maternal-fetal ultrasound indicators for preeclampsia(PE) and to analyze delivery outcomes associated with PE.
methodsPregnant women with PE(n = 80) and healthy controls(n = 160) were enrolled from the People's Hospital of Guangxi Zhuang Autonomous Region between 2021 and 2022. Serum PLGF level were measured at various stages of pregnancy: early pregnancy, mid-pregnancy, and late pregnancy. Maternal clinical features, fetal ultrasound indicators, and pregnancy outcomes were also recorded.
resultsThe serum concentration of PLGF was lower in the PE group compared to the control group throughout early, middle, and late pregnancy. At 20-24 weeks, the uterine artery resistance index was higher in the preeclampsia group (P < 0.05). Logistic regression analysis identified PLGF concentrations in early pregnancy and mid-pregnancy, along with mean arterial pressure (MAP), as independent factors for the onset of PE (P < 0.05).
conclusionPLGF could be used for prediction of PE in early pregnancy. A predictive model for PE was established by combining the PLGF concentrations in early and middle pregnancy with MAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.